First-Line MS Treatment Decisions: Guiding the Newly Diagnosed Patient

In this episode focused on first-line MS treatments, Dr. Williams poses the practical question: when a newly diagnosed, treatment-naive patient with relapsing-remitting MS sits across from you, what guides your treatment recommendation?

Dr. Krieger acknowledges the challenge posed by the new McDonald criteria — some patients diagnosed under expanded definitions have very limited supporting trial data. For patients with definitive clinical MS, Dr. Krieger describes a shared decision-making approach constrained to three or four reasonable, individualized options. He now always includes at least one high-efficacy therapy in that shortlist, as well as an S1P receptor modulator as a high-efficacy oral option. Platform injectables, he notes, have not been part of his practice for years.

He describes lesion localization as the most important prognostic factor: lesions in the spinal cord, brainstem, and cerebellum carry the greatest risk of crossing the clinical threshold into disability. Overall lesion burden and clinical presentation severity at onset further inform the urgency of aggressive treatment. Family planning considerations, informed by Dr. Bove's expertise, are also woven in from the beginning — allowing patients to see that high-efficacy treatment and a fulfilling personal life are not in conflict.

In the next episode, "Why Anti-CD20 Therapy Has Become a Cornerstone of MS Treatment," the panel explores B-cell targeting as a therapeutic strategy and the reasons anti-CD20 agents have risen to frontline status in MS management.